First Dallas Securities’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

First Dallas Securities’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-26,710	Closed	-$395K	–	116
2017 Q1	$395K	Buy	26,710 +2,300	+9%	+$37.3K	0.28%	71
2016 Q4	$395K	Sell	24,410 -5,520	-18%	-$100K	0.27%	71
2016 Q3	$542K	Sell	29,930 -2,500	-8%	-$48.8K	0.4%	58
2016 Q2	$534K	Buy	32,430 +2,850	+10%	+$46.1K	0.41%	52
2016 Q1	$490K	Buy	+29,580	New	+$518K	0.4%	54

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

First Dallas Securities's HZNP Position: Q2 2017 in Review

First Dallas Securities sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 26,710 shares — an estimated $395K sold.

First Dallas Securities first reported a position in HZNP in Q1 2016 and held it in 5 quarters. The position peaked at $542K in Q3 2016. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

First Dallas Securities reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
First Dallas Securities sold 26,710 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $395K.
First Dallas Securities first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2016 and held it in 5 quarters.
First Dallas Securities's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $542K in Q3 2016.
190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on First Dallas Securities's 13F filing for Q2 2017, filed 14 Aug 2017.